U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07231770) titled 'Sulfamethoxazole Prophylaxis Duration After Renal Transplantation' on Nov. 14.
Brief Summary: Renal transplantation is the most ideal and effective treatment for end-stage renal disease. Pneumocystis jirovecii pneumonia (PJP) is one of the most common pulmonary infections after renal transplantation, with high morbidity and mortality that seriously affects patients' prognosis and survival. PJP can be prevented with drugs, and trimethoprim-sulfamethoxazole (TMP-SMX) is the first-choice prophylactic agent. However, there is no clear definition of the prophylactic course of TMP-SMX in domestic and international guidelines. Most of the ...